idarubicin second-gener anthracyclin vitro activ leukem cell line phase studi acut leukemia phase II iii clinic trial idarubicin hydrochlorid patient acut lymphocyt leukemia acut nonlymphocyt leukemia phase iii compar trial combin idarubicin cytarabin daunorubicin hydrochlorid cytarabin idarubicin/cytarabin combin complet remiss rate overal surviv studi US result food drug administr intraven idarubicin class rate septemb use combin antileukem drug cytarabin treatment acut myelogen leukemia adult recommend dose idarubicin day slow intraven inject combin cytarabin idarubicin caus myelosuppress similar daunorubicin incid cardiotox anim model idarubicin advantag oral administr oral formul drug investig use idarubicin pediatr patient 